Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Coagulation factor VIII (FVIII) is an essential blood clotting protein acting as a cofactor for activated factor IX (FIXa) in the activation of factor X. Deficiency or mutations in FVIII cause hemophilia A, a bleeding disorder. FVIII circulates bound to von Willebrand factor (vWF) and is activated by thrombin. Therapeutic innovations include recombinant FVIII products, gene therapy, and bispecific antibodies.
Cofactor for FIXa-mediated activation of FX in the coagulation cascade, leading to thrombin generation and fibrin clot formation
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Coagulation Factor VIII (FVIII).